Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omeros: Q1 Earnings Snapshot

05/10/2021 | 04:49pm EDT

SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $35.1 million in its first quarter.

On a per-share basis, the Seattle-based company said it had a loss of 57 cents. Losses, adjusted for non-recurring costs, came to 50 cents per share.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share.

The drug developer posted revenue of $21.1 million in the period.

Omeros shares have risen 24% since the beginning of the year. In the final minutes of trading on Monday, shares hit $17.69, a climb of 11% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OMER at https://www.zacks.com/ap/OMER

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about OMEROS CORPORATION
08/09OMEROS : Q2 Loss Narrows on Rising Revenue -- Stock Up 3% After-Hours
MT
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERAT..
AQ
08/09OMEROS CORP : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
08/09OMEROS CORPORATION : Reports Second Quarter 2021 Financial Results
BU
08/09Omeros Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/03OMEROS CORPORATION : to Announce Second Quarter Financial Results on August 9, 2021
BU
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Statements an..
AQ
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 112 M - -
Net income 2021 -122 M - -
Net Debt 2021 258 M - -
P/E ratio 2021 -8,28x
Yield 2021 -
Capitalization 992 M 992 M -
EV / Sales 2021 11,1x
EV / Sales 2022 6,75x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 15,88 $
Average target price 27,00 $
Spread / Average Target 70,0%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION11.17%992
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634